Aethlon Medical Dirección

Dirección controles de criterios 2/4

El CEO de Aethlon Medical's es Jim Frakes, nombrado en Jan 2008, tiene una permanencia de 16.25 años. posee directamente un 0.009% de las acciones de la empresa, con un valor de $350.59. La antigüedad media del equipo directivo y de la junta directiva es de 2.2 años y 6.4 años, respectivamente.

Información clave

Jim Frakes

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	16.3yrs
Participación del CEO	0.009%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	6.5yrs

Actualizaciones recientes de la dirección

Recent updates

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Aug 02

FDA approves protocol change in Aethlon's trial of its purifier to treat severe COVID

Jul 11

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Mar 18

We're Interested To See How Aethlon Medical (NASDAQ:AEMD) Uses Its Cash Hoard To Grow

Nov 09

Aethlon Medical (AEMD) rockets 63% as FDA amends Hemopurifier IDE for COVID-10 treatment

Dec 16

Aethlon names Charles J. Fisher, Jr., M.D. as CEO

Nov 03

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jim Frakes en comparación con los beneficios de Aethlon Medical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$12m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$12m
Dec 31 2022	n/a	n/a	-US$13m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	-US$10m
Dec 31 2021	n/a	n/a	-US$9m
Sep 30 2021	n/a	n/a	-US$9m
Jun 30 2021	n/a	n/a	-US$9m
Mar 31 2021	US$582k	US$275k	-US$8m
Dec 31 2020	n/a	n/a	-US$7m
Sep 30 2020	n/a	n/a	-US$6m
Jun 30 2020	n/a	n/a	-US$6m
Mar 31 2020	US$355k	US$264k	-US$6m
Dec 31 2019	n/a	n/a	-US$6m
Sep 30 2019	n/a	n/a	-US$7m
Jun 30 2019	n/a	n/a	-US$7m
Mar 31 2019	US$286k	US$256k	-US$6m
Dec 31 2018	n/a	n/a	-US$6m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	US$235k	US$235k	-US$6m

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Jim es razonable en comparación con empresas de tamaño similar en el mercado US.

Compensación vs. Ingresos: La compensación de Jim ha aumentado mientras la empresa no es rentable.

CEO

Jim Frakes (66 yo)

16.3yrs

Permanencia

US$581,661

Compensación

Mr. James B. Frakes, also known as Jim, M.B.A. has been the Chief Financial Officer at Aethlon Medical, Inc. since January 2008 and serves as its Interim Chief Executive Officer and Director since November...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Guy Cipriani	Chief Operating Officer	less than a year	US$347.50k	0.068% $ 2.5k
Steven LaRosa	Chief Medical Officer	3.3yrs	US$430.00k	0% $ 0
James Frakes	Interim CEO	16.3yrs	US$581.66k	0.0090% $ 329.3
Lee Arnold	Chief Scientific Officer	1.3yrs	sin datos	sin datos

2.3yrs

Permanencia media

59.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AEMD se considera experimentado (2.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
James Frakes	Interim CEO	less than a year	US$581.66k	0.0090% $ 329.3
Edward Broenniman	Independent Chairman of the Board	25.2yrs	US$147.50k	0.48% $ 17.5k
Nathan Levin	Member of Extracorporeal Therapy Advisory Board	no data	sin datos	sin datos
Gregory T. Kovacs	Member of Extracorporeal Therapy Advisory Board	no data	sin datos	sin datos
Claudio Ronco	Member of Extracorporeal Therapy Advisory Board	no data	sin datos	sin datos
Larry Cowgill	Member of Sepsis & Inflammation Advisory Board	no data	sin datos	sin datos
Charles Fisher	Member of Extracorporeal Therapy Advisory Board	no data	US$460.00k	0.075% $ 2.7k
John Kellum	Member of Extracorporeal Therapy Advisory Board	no data	sin datos	sin datos
Chetan Shah	Independent Director	10.9yrs	US$117.50k	0.44% $ 16.2k
David Ward	Member of Extracorporeal Therapy Advisory Board	no data	sin datos	sin datos
Irshad Chaudry	Member of Sepsis & Inflammation Advisory Board	no data	sin datos	sin datos
Angela Rossetti	Independent Director	2.1yrs	US$138.00k	6.4% $ 233.0k

6.5yrs

Permanencia media

70yo

Promedio de edad

Junta con experiencia: La junta directiva de AEMD se considera experimentada (6.4 años de antigüedad promedio).

Aethlon Medical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2023

Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2022

Insufficient new directors

Aethlon Medical, Inc. Announces Executive Changes

Recent updates

Aethlon Medical, Inc. has filed a Follow-on Equity Offering in the amount of $16.32 million.

Price target increased by 27% to US$40.10

Aethlon Medical, Inc. to Report Q3, 2024 Results on Feb 14, 2024

New major risk - Financial position

Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer

Aethlon Medical, Inc. to Report Q2, 2024 Results on Nov 14, 2023

Price target decreased by 21% to US$31.55

Price target decreased by 90% to US$4.01

Aethlon Medical, Inc. Receives Clearance from Drug Controller General of India for Potential Phase 1 Trial of its Hemopurifier(R) in Oncology

Aethlon Medical, Inc. to Report Q1, 2024 Results on Aug 10, 2023

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2023

Price target decreased by 12% to US$6.50

Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee

New major risk - Shareholder dilution

Full year 2023 earnings released: US$0.59 loss per share (vs US$0.71 loss in FY 2022)

Aethlon Medical, Inc. to Report Q4, 2023 Results on Jun 28, 2023

New major risk - Share price stability

No longer forecast to breakeven

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2022)

Aethlon Medical, Inc. to Report Q3, 2023 Results on Feb 13, 2023

Forecast to breakeven in 2023

No longer forecast to breakeven

First half 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 1H 2022)

Aethlon Medical, Inc. to Report Q2, 2023 Results on Nov 14, 2022

Aethlon Medical Receives Non-Compliance Notice of Delisting from Nasdaq

Aethlon Medical, Inc. Announces Early Feasibility Study of the Hemopurifier

Forecast to breakeven in 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aethlon Medical, Inc. to Report Q1, 2023 Results on Aug 09, 2022

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2022

Aethlon Medical, Inc. Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment

FDA approves protocol change in Aethlon's trial of its purifier to treat severe COVID

Consensus revenue estimates fall by 100%

Aethlon Medical, Inc. to Report Fiscal Year 2022 Results on Jun 28, 2022

Price target decreased to US$7.00

Consensus revenue estimates increase by 178%

Insufficient new directors

Consensus revenue estimates increase by 178%

Aethlon Medical, Inc. Announces Executive Changes

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Consensus revenue estimates fall by 68%

Aethlon Medical, Inc. to Report Q3, 2022 Results on Feb 14, 2022

Insufficient new directors

We're Interested To See How Aethlon Medical (NASDAQ:AEMD) Uses Its Cash Hoard To Grow

Consensus revenue estimates fall to US$1.24m

Full year 2021 earnings released: US$0.65 loss per share (vs US$1.87 loss in FY 2020)

Aethlon Medical climbs on Reddit interest

Aethlon Medical, Inc. Publishes Case Studies of Two Critically ill Covid-19 Patients Treated with the Hemopurifier®

Forecast to breakeven in 2023

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Revenue and earnings beat expectations

New 90-day high: US$2.81

Aethlon Medical, Inc. to Report Q3, 2021 Results on Feb 10, 2021

We're Hopeful That Aethlon Medical (NASDAQ:AEMD) Will Use Its Cash Wisely

Aethlon Medical, Inc. Announces Executive Appointments

Aethlon Medical has a new business and medical chief

Independent Director recently sold US$57k worth of stock

Aethlon Medical, Inc. Announces First Patient Treated in First-in-Human Clinical Trial of HEMOPURIFIER® in Head and Neck Cancer

New 90-day high: US$2.26

Aethlon Medical (AEMD) rockets 63% as FDA amends Hemopurifier IDE for COVID-10 treatment

Aethlon Medical, Inc. Announces Board Changes, Effective as of October 30, 2020

Aethlon Medical, Inc. Announces Executive Changes, Effective as of October 30, 2020

Aethlon names Charles J. Fisher, Jr., M.D. as CEO

First half earnings released

Aethlon Medical, Inc. to Report Q2, 2021 Results on Oct 28, 2020

New 90-day low - US$1.29

First quarter earnings released

Aethlon Medical, Inc. to Report Q1, 2021 Results on Aug 11, 2020